What plan is associated with GSK’s new share admission in 2026?

The additional 45,273 GSK ordinary shares admitted to trading are connected with the “GlaxoSmithKline plc Share Save Plan 2022”. This employee-related plan operates under existing block listing admissions for GSK’s ordinary shares on the London Stock Exchange.

GSK admits 45,273 new shares to trading

GSK plc has admitted a further 45,273 ordinary shares of 31¼ pence each to trading on the London Stock Exchange Main Market.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

GSK plc has admitted a further 45,273 ordinary shares of 31¼ pence each to trading on the London Stock Exchange Main Market. These shares were issued under existing block listing admissions for the “GlaxoSmithKline plc Share Save Plan 2022”. Following this admission, a total of 4,316,221,551 GSK ordinary shares are admitted to trading, and the new shares are fully fungible with existing ordinary shares.

Key Figures

New shares admitted: 45,273 shares Total shares admitted: 4,316,221,551 shares Nominal value per share: 31¼ pence +1 more

4 metrics

New shares admitted 45,273 shares Further ordinary shares admitted to trading

Total shares admitted 4,316,221,551 shares Total GSK ordinary shares after admission

Nominal value per share 31¼ pence Nominal value of each ordinary share

Notification date range 27 March 2026 - 22 May 2026 Period covered by the admission notification

Key Terms

block listing admissions, Share Save Plan 2022, fungible, Form 20-F, +1 more

5 terms

block listing admissions regulatory

"admitted to trading under existing block listing admissions of Ordinary Shares"

fungible financial

"Fungibility | Fully fungible with existing Ordinary Shares"

Fungible describes an asset that is interchangeable with another of the same kind because each unit holds the same value and function. For investors this matters because fungible assets are easier to trade, price, and store—think of cash or grains where one unit can replace another, unlike a unique artwork or a signed collectible which may be worth more or less depending on provenance. Fungibility affects liquidity, market efficiency, and how assets are settled or regulated.

Form 20-F regulatory

"whether the registrant files or will file annual reports under cover of Form 20-F"

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did GSK (GSK) disclose in this May 2026 Form 6-K?

GSK disclosed that 45,273 additional ordinary shares have been admitted to trading on the London Stock Exchange Main Market. These shares arise under existing block listings linked to the GlaxoSmithKline plc Share Save Plan 2022, increasing total admitted shares to 4,316,221,551.

How many new GSK (GSK) shares were admitted to trading?

GSK admitted 45,273 further ordinary shares of 31¼ pence each to trading. These additional shares were issued under existing block listing admissions connected with the GlaxoSmithKline plc Share Save Plan 2022 on the London Stock Exchange Main Market.

What is GSK’s total number of shares admitted after this change?

After admitting 45,273 further ordinary shares, GSK now has 4,316,221,551 ordinary shares admitted to trading. This figure represents the total number of GSK ordinary shares listed on the London Stock Exchange Main Market following the latest admission.

On which market are GSK’s newly admitted shares trading?

The newly admitted GSK ordinary shares are trading on the London Stock Exchange Main Market. They are fully fungible with existing ordinary shares, meaning they are treated identically for trading and settlement purposes on this regulated market.

Over what period were GSK’s further shares covered by this notification?

The notification covers the period from 27 March 2026 to 22 May 2026. During this date range, 45,273 additional GSK ordinary shares associated with the Share Save Plan 2022 were admitted to trading under existing block listing admissions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/26/2026 - 10:23 AM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Issued: 26 May 2026, London UK

Admission to trading

In conformity with PRM 1.6.4R, GSK plc notifies the market that ordinary shares of 31¼ pence each ('Ordinary Shares') have been admitted to trading as set out in the table below. The Ordinary Shares have been admitted to trading under existing block listing admissions of Ordinary Shares in connection with the "GlaxoSmithKline plc Share Save Plan 2022".

1a	Issuer name	GSK plc
1b	Issuer LEI	5493000HZTVUYLO1D793
2	Regulated market on which the securities have been admitted to trading	London Stock Exchange - Main Market
3	Name, type and ISIN of the securities	Ordinary Shares of 31¼ pence each ISIN: GB00BN7SWP63
4	Number of further securities admitted to trading covered by this notification	45,273
5	Total number of securities admitted to trading following admission	4,316,221,551
6	Fungibility	Fully fungible with existing Ordinary Shares
7	Date range covered by the notification	27 March 2026 - 22 May 2026
8	Prospectus information	N/A

V A Whyte

Company Secretary

26 May 2026

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

	GSK plc
	(Registrant)

Date: May 26, 2026

	By:/s/ VICTORIA WHYTE --------------------------

	Victoria Whyte
	Authorised Signatory for and on
	behalf of GSK plc

Source: View Original Filing on SEC EDGAR